-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Redefining Frontline Therapy in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

Sponsor: Johnson & Johnson
Program: Product Theaters
Hematology Disease Topics & Pathways:
Treatment Considerations, Non-Biological therapies
Sunday, December 8, 2024: 8:00 AM-9:00 AM
Room 1B (San Diego Convention Center)
Speaker:
Marjohn Armoon, PharmD, Johnson & Johnson
Disclosures:
No relevant conflicts of interest to declare.

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only
See more of: Product Theaters
<< Previous Product Theater | Next Product Theater >>